FY2024 Earnings Estimate for Corvus Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:CRVS)

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for shares of Corvus Pharmaceuticals in a report released on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will post earnings of ($0.35) per share for the year, up from their previous forecast of ($0.53). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Corvus Pharmaceuticals' current full-year earnings is ($0.51) per share.

Other equities analysts have also issued research reports about the company. Mizuho reissued a "neutral" rating and issued a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday, March 27th. Oppenheimer decreased their target price on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating for the company in a research report on Wednesday, March 20th.

Corvus Pharmaceuticals Trading Down 3.4 %

NASDAQ:CRVS traded down $0.06 during mid-day trading on Thursday, reaching $1.69. The company's stock had a trading volume of 211,054 shares, compared to its average volume of 219,692. Corvus Pharmaceuticals has a 12-month low of $0.95 and a 12-month high of $4.19. The firm's fifty day moving average price is $2.06 and its two-hundred day moving average price is $1.76. The stock has a market cap of $82.88 million, a P/E ratio of -2.96 and a beta of 1.02.

Institutional Investors Weigh In On Corvus Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in CRVS. Marshall Wace LLP purchased a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $685,000. Towerview LLC increased its position in shares of Corvus Pharmaceuticals by 67.1% during the 3rd quarter. Towerview LLC now owns 342,478 shares of the company's stock valued at $500,000 after purchasing an additional 137,478 shares during the last quarter. Two Sigma Advisers LP increased its position in shares of Corvus Pharmaceuticals by 28.6% during the 3rd quarter. Two Sigma Advisers LP now owns 480,100 shares of the company's stock valued at $393,000 after purchasing an additional 106,700 shares during the last quarter. Goldman Sachs Group Inc. purchased a new stake in shares of Corvus Pharmaceuticals during the 2nd quarter valued at about $216,000. Finally, Two Sigma Investments LP grew its stake in shares of Corvus Pharmaceuticals by 19.0% during the 3rd quarter. Two Sigma Investments LP now owns 429,708 shares of the company's stock valued at $352,000 after acquiring an additional 68,674 shares during the period. Hedge funds and other institutional investors own 46.64% of the company's stock.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase I/Ib clinical trial for non-small cell lung cancer and head and neck cancers.